BioHorizon Health Technology Surveillance Update: February 8, 2010

The BioHorizon Health Technology Surveillance Update gives readers a concise,  high level overview of the most important emerging health technology developments on a ongoing basis  including key FDA approvals, substantive clinical trial results and upcoming events of importance.
First of all, on behalf of  the entire BioHorizon staff, let me welcome you to the BioHorizon Health Technology [...]

Surveillance Summary Apr 3 – Apr 9, 2004

Our emerging health technology surveillance system experienced light activity throughout Week 15 of 2004 with a total of 12 technologies updated. Of these, 5 were new detects and 7 were already present in the Biohorizon database. The average impact score was 36, down 6 from last week. A fairly narrow spectrum of target diseases was [...]

Surveillance Summary Mar 27 – Apr 2, 2004

The Biohorizon emerging health technology surveillance system experienced moderate to heavy activity throughout Week 14 of 2004 with a total of 23 updated technologies. Of these, 2 were new detects while 21 were already present in the Biohorizon database. The average impact score was 42, up two from last week. A broad spectrum of [...]

Surveillance Summary March 20 – 26, 2004

Our emerging health technology database experienced light activity throughout Week 13 of 2004 with 14 technology updates. 1 High Impact Technology, 8 Moderate Impact Technologies, and 5 Low Impact Technologies were updated. The mean impact score for the week was 40, up three from last week. Of note, 6 of the updated technologies [...]

Surveillance Summary March 13 – 19, 2004

Our emerging health technology database experienced light activity throughout Week 12 of 2004 with 10 technology updates. 8 Moderate Impact Technologies and 2 Low Impact Technologies were updated. None of the 10 updates were for newly detected technologies and, for the first time in 2004, no technology updates occurred in the High Impact category. [...]

Surveillance Summary March 6 – 12, 2004

23 technologies were updated or added to the Biohorizon Emerging Health Technology Database in Week 11. This represents moderate activity and places Week 11 as the most active week so far in 2004. 2 of the updated technologies, Daxas and Acomplia, were designated as High Impact Health Technologies, 18 received a Moderate Impact score, [...]

Surveillance Summary Feb 25 – March 5, 2004

Our surveillance program experienced light activity throughout Week 10 of 2004. A total of 18 technology updates were recorded; 4 of these were new additions to the Biohorizon Emerging Health Technology Database (new detects), while the remaining 14 were updates made to existing technology records. This week’s average Health Technology Impact Score is 45, up [...]

Surveillance Summary Feb 14 – Feb 20, 2004

Our surveillance program experienced light activity throughout Week 8 of 2004. A total of 20 technology updates were recorded; 2 of these were newly detected technologies added to our database (New Detects), while 18 updates were made to already existing technology records. This week’s average Health Technology Impact Score was 41.85, slightly above the [...]

Surveillance Summary Feb 7 – Feb 13, 2004

Our surveillance program experienced moderate activity throughout week 7 of 2004. A total of 19 technology updates were recorded; 12 of these were new technologies added to our database, while the remaining 7 updates occurred for already existing technology records. Etanercept, Remicade and Visudyne were the only High Impact technologies updated during week [...]

Surveillance Summary Jan 31 – Feb 6, 2004

Our surveillance program experienced heavy activity throughout week 6 of 2004. A total of 27 technology updates were recorded; 9 of these were new technologies added to our Emerging Health Technology Database (‘new detects’), while the remaining 18 updates occurred for already existing technology records. 8 of the 18 or 44% are [...]